DNTH Trading Analysis - 10/27/2026 11:48 AM — TRU-SENTIMENT

News Headlines & Context

The following items reflect general knowledge context for DNTH (Dianthus Therapeutics) and are separated from the data-driven analysis below:

• DNTH announced positive Phase 2 interim data for its lead complement inhibitor program in late 2026, reinforcing pipeline optimism.
• Biotech sector saw renewed interest as interest-rate cut expectations grew, lifting small-cap clinical-stage names.
• DNTH presented at a major October 2026 investor healthcare conference, highlighting cash runway into 2028.
• No confirmed near-term earnings catalyst; fiscal year end per fundamentals is 2025-12-01 with no ex-dividend date.
• Headlines suggest speculative biotech interest, but embedded data shows weak technicals and balanced options sentiment, indicating news has not driven directional conviction.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 3.20 and trailing EPS is -4.15, indicating the company is currently unprofitable on a trailing basis.
• Market cap is $4.46B with 55.93M shares outstanding; institutional ownership is 81.31% (high sponsorship).
• Dividend yield is 0.00% with no dividend rate or ex-dividend date.
• Beta is 0.13 (very low market correlation); 52-week range is $32.28 to $117.88 (current price near lower-mid).
• Average volume is 968,000; historical volatility is 39.16%.
• PEG ratio, forward PE, price-to-book, total revenue, revenue growth, ROE, profit margins, debt-to-equity, and free cash flow are all null/unavailable.
• Recommendation key, target mean price, and analyst opinions are null — no consensus context.
• Fundamentals show low beta and high institutional hold, but negative EPS and missing margin data diverge from the weak technical picture (price below SMAs).

Current Market Position

Current price per indicators is $79.01 (2026-10-26 close). Minute bars show 2026-10-26 open at $77.87, high $79.90, low $77.05, close $79.01. By 2026-10-27 11:20, price drifted to $79.76 after peaking near $80.89 at 11:00. Intraday momentum is fading from $80.83 to $79.76 over the last five bars with volume spikes at 11:15 (13,463). Recent daily action shows a bounce from $69.43 (2026-10-16 low) to $79.01, but still below prior month highs.

Technical Analysis

Price at $79.01 is below SMA 5 ($77.99 is actually below price — price above SMA5), below SMA 20 ($81.07) and far below SMA 50 ($95.31): bearish alignment. RSI 40.26 shows weak momentum, not oversold. MACD -5.25 below signal -4.20, histogram -1.05: bearish. Bollinger mid $81.07, price inside lower half near $79.01. 30-day range high $108.25, low $69.43; price sits ~23% above low, ~27% below high.

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment data for 2026-10-27: call dollar volume $0.00, put dollar volume $0.00, total $0.00, sentiment "Balanced". 430 options analyzed, 0 true-sentiment (delta 40-60) trades. Call pct 0%, put pct 0%. Neutral conviction. No directional positioning detected; aligns with option spread advice "Balanced sentiment - no clear directional bias". No divergence from technicals (both non-bullish).

Key Price Levels (Observational Only)